Talaris Therapeutics

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Our mission is to develop and deliver treatments to patients with rare and intractable genetic diseases.

Our vision is to create a world where no rare disease goes untreated.

Talaris is the recipient of several awards, including $25 million from Centers for Medicare and Medicaid Services Innovation Award, $50 million from Orphan Disease Center Fast Track, and $12.5 million from California Institute for Regenerative Medicine Incentive Award.